IXICO signs new contract for imaging services
Ixico
8.62p
16:49 26/04/24
Digital technologies company IXICO announced that it has signed a new contract with an unnamed customer on Thursday, for its technology-enabled imaging services.
FTSE AIM All-Share
755.28
17:14 26/04/24
Pharmaceuticals & Biotechnology
22,773.26
16:59 26/04/24
The AIM-traded firm said the contract value was $0.69m over a two-and-a-half-year term.
It said the new contract was for a Phase II clinical trial evaluating the safety and tolerability of a “novel treatment” for patients with Huntington's disease.
As part of the study, IXICO would use its ‘TrialTracker’ digital platform and scientific services to provide a battery of advanced MRI imaging techniques and clinical trial endpoints.
“We are delighted to announce this contract, building on our successful track record as the partner of choice in Huntington's disease clinical studies,” said CEO Giulio Cerroni.
“This new contract further demonstrates the value our customers see in IXICO's deep neurological disease expertise combined with our proprietary digital technologies in providing compliant data standardisation, collection and analysis.”